Blog
RSS FeedPosted by Michael Wonder on 16 Aug 2020
Direct or indirect comparison: reliance on innovative drug data key to engaging data protection
15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...
Posted by Michael Wonder on 12 Aug 2020
Rare disease drugs strategy, standard coverage in CLHIA’s 2020 budget wish list
12 August 2020 - The Canadian Life and Health Insurance Association is recommending the federal government develop a strategy for ...
Posted by Michael Wonder on 10 Aug 2020
Can multi-criteria decision analysis be implemented into real world drug decision-making processes? A Canadian provincial experience
7 August 2020 - This paper describes the implementation of multi-criteria decision analysis into a Canadian public drug reimbursement decision-making process, ...
Posted by Michael Wonder on 10 Aug 2020
Return some excess drug revenues to employers, CLHIA says in submission to PMPRB
10 August 2020 - In its submission to the Patented Medicine Prices Review Board’s draft guidelines, the Canadian Life and ...
Posted by Michael Wonder on 10 Aug 2020
B.C. family nearing finish in race to raise $2.8 million to treat baby's rare disease
8 August 2020 - Parents hope funds will pay for expensive therapy not approved in Canada for type 1 spinal muscular ...
Posted by Michael Wonder on 04 Aug 2020
Innovative Medicines Canada responds to the revised draft PMPRB Guidelines consultation
4 August 2020 - The Patented Medicine Prices Review Board's revised Guidelines will result in patients losing access to innovative ...
Posted by Michael Wonder on 28 Jul 2020
CADTH publishes final recommendation for a new combination product for HIV infection
24 July 2020 - Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) is indicated as a complete regimen for the treatment ...
Posted by Michael Wonder on 27 Jul 2020
CADTH posts final recommendation for Aimovig
26 July 2020 - Final recommendation informed by input from Migraine Canada and Migraine Quebec. ...
Posted by Michael Wonder on 26 Jul 2020
'I need something to move forward,' says Edmonton mom waiting for approval for son's life saving treatment
24 July 2020 - The family of a little boy in need of a $3 million treatment says they have ...
Posted by Michael Wonder on 23 Jul 2020
CADTH publishes final recommendation for Mayzent
23 July 2020 - The recommendation relates to the use of siponomid for the treatment of patients with secondary progressive multiple ...
Posted by Michael Wonder on 22 Jul 2020
Pandemic creating potential for drug shortages that Canada isn't equipped to deal with
22 July 2020 - Canada needs to become self-reliant in developing and supplying its own critical drugs, vaccines. ...
Posted by Michael Wonder on 20 Jul 2020
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price
20 July 2020 - CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. ...
Posted by Michael Wonder on 20 Jul 2020
CADTH publishes final recommendation for Stelara
20 July 2020 - CADTH has completed its assessment of ustekinumab by intravenous injection for the treatment of adult patients ...
Posted by Michael Wonder on 18 Jul 2020
'Heartbreaking': Alberta families describe waiting for life-changing drug to be made available in Canada
17 July 2020 - More families are hoping a one-time treatment option for a rare condition will be made available ...
Posted by Michael Wonder on 14 Jul 2020
Dupixent (dupilumab) receives positive recommendation from INESSS for the treatment of moderate to severe atopic dermatitis in adolescents
14 July 2020 - The Institut national d'excellence en santé et en services sociaux (INESSS) recommends extending existing coverage in Quebec ...